Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Arthritis Research & Therapy

Figure 2

From: Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment

Figure 2

Mean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) in patients with axial spondyloarthritis before and after 12 and 36 to 52 weeks of treatment with adalimumab. *P < 0.05. ns, not significant.

Back to article page